Flexion Therapeutics (FLXN)
ChartMill assigns a Buy % Consensus number of 79% to FLXN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.62. This target is 38.4% above the current price.
FLXN was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about FLXN.
In the previous month the buy percentage consensus was at a similar level.
FLXN was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-11-19 | Northland Capital Markets | Downgrade | Outperform -> Market Perform |
| 2021-10-19 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-10-12 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2021-10-12 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2021-10-12 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2021-08-06 | Goldman Sachs | Maintains | Neutral |
| 2021-08-05 | Needham | Maintains | Buy |
| 2021-05-13 | Credit Suisse | Maintains | Outperform |
| 2021-04-14 | Raymond James | Maintains | Strong Buy |
| 2021-04-14 | Credit Suisse | Maintains | Outperform |
| 2021-03-11 | Credit Suisse | Maintains | Outperform |